Search

Your search keyword '"Katagiri, Yuki"' showing total 328 results

Search Constraints

Start Over You searched for: Author "Katagiri, Yuki" Remove constraint Author: "Katagiri, Yuki"
328 results on '"Katagiri, Yuki"'

Search Results

3. Geographic disparity of pathophysiological coronary artery disease characteristics: Insights from ASET trials

5. CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) update 2022

8. The neuromodulatory role of dopamine in improved reaction time by acute cardiovascular exercise

10. Endothelial shear stress and vascular remodeling in bioresorbable scaffold and metallic stent

12. TCT-317 Acute Results of Optical Coherence Tomography-Guided Percutaneous Coronary Intervention With Intravascular Lithotripsy Versus Orbital/Rotational Atherectomy in Calcified Lesions: A Propensity-Matched Comparison

13. TCT-600 Evaluation of the Stent Parameters Post-PCI (Minimum Stent Area, Stent Expansion Index, and Stent Gradient) and its Relation to Post-PCI Physiological Outcomes Assessed by Intravascular Imaging-Based Ultrasonic Flow Ratio and Optical Flow Ratio: Insights From the ASET JAPAN Trial

14. Clinical Implication of Quantitative Flow Ratio After Percutaneous Coronary Intervention for 3-Vessel Disease

15. Reduced-dose prasugrel monotherapy without aspirin after PCI with the SYNERGY stent in East Asian patients presenting with chronic coronary syndromes or non-ST-elevation acute coronary syndromes: rationale and design of the ASET Japan pilot study

16. Angiography-Derived Fractional Flow Reserve in the SYNTAX II Trial: Feasibility, Diagnostic Performance of Quantitative Flow Ratio, and Clinical Prognostic Value of Functional SYNTAX Score Derived From Quantitative Flow Ratio in Patients With 3-Vessel Disease

18. A 30-Day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) in Brazil and Japan: Synergy Stent with Prasugrel Monotherapy Without Aspirin

20. Fractional Flow Reserve Derived From Computed Tomographic Angiography in Patients With Multivessel CAD

21. A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial

23. The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial

26. TCTAP A-046 A 30-Day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) In Brazil and Japan: Synergy Stent With Prasugrel Monotherapy Without Aspirin

27. Prasugrel Monotherapy After Percutaneous Coronary Intervention With Biodegradable-Polymer Platinum-Chromium Everolimus Eluting Stent for Japanese Patients With Chronic Coronary Syndrome (ASET-JAPAN)

28. Impact of Fractional Flow Reserve Derived From Coronary Computed Tomography Angiography on Heart Team Treatment Decision-Making in Patients With Multivessel Coronary Artery Disease: Insights From the SYNTAX III REVOLUTION Trial

29. CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) in 2018

30. CRT-100.33 A 30-Day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) in Brazil and Japan: Synergy Stent with Prasugrel Monotherapy Without Aspirin

32. Features and Outcomes of Histologically Proven Myocarditis With Fulminant Presentation

35. TCT-14 A 30-Day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) After PCI in Brazil and Japan: SYNERGY Stent With Prasugrel Monotherapy (10 mg or 3.75 mg)

36. Imaging assessment of bioresorbable vascular scaffolds

37. Single or dual antiplatelet therapy after PCI

39. Impact of Coronary Remodeling on Fractional Flow Reserve

40. Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug‐Eluting Stent Implantation: Per‐Protocol Analysis of the GLOBAL LEADERS Trial

42. Online three-dimensional OFDI-guided versus angiography-guided PCI in bifurcation lesions: design and rationale of the randomised OPTIMUM trial: Online 3D OFDI-guided bifurcation PCI

43. The Influence of Implantation Techniques on Lesion-Oriented Outcomes in Absorb BVS and Xience EES Lesions Treated in Routine Clinical Practice at Complete Three-Year Follow-Up - AIDA Trial QCA Substudy

44. Risk Factors and Outcomes of Recurrent Drug‐Eluting Stent Thrombosis: Insights From the REAL‐ST Registry

45. Online three-dimensional OFDI-guided versus angiography-guided PCI in bifurcation lesions: design and rationale of the randomised OPTIMUM trial

48. Neointimal hyperplasia of ultra-thin stents with microcrystalline sirolimus or durable polymer everolimus-eluting stents: 6- and 24-month results of the DESSOLVE III OCT study

49. Vulnerable plaques and patients: state-of-the-art

50. Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents. A pooled analysis of individual patient data from 2 randomized trials

Catalog

Books, media, physical & digital resources